Immunotherapeutic strategies for bladder cancer

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 977-981

  Chevalier, Mathieu F ^a   Nardelli Haefliger, Denise ^a   Domingos Pereira, Sonia ^a   Jichlinski, Patrice ^a   Derré, Laurent ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

BCG therapy; Bladder cancer; Combinatorial strategies; Immunostimulants; Immunotherapy; Mucosal homing; Therapeutic vaccination; Vaccination routes

Indexed keywords

ASUDEMOTIDE; BCG VACCINE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; PROTEIN E7; TREMPAMOTIDE; TUMOR ANTIGEN;

ALLERGIC REACTION; BLADDER CANCER; BLADDER CONTRACTURE; BLADDER DISEASE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYSTITIS; DYSURIA; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; LYMPHOCYTE HOMING; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); SEPSIS; TREATMENT RESPONSE; TUMOR IMMUNITY; URINARY URGENCY; AGED; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

AGED; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84899881177     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27621     Document Type: Note

References (35)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765-81; PMID:20116997; http://dx.doi.org/10.1016/j.ejca.2009.12.014
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
3. Nielsen ME, Smith AB, Meyer AM, Kuo TM, Tyree S, Kim WY, Milowsky MI, Pruthi RS, Millikan RC. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer 2014; 120:86-95; PMID:24122346; http://dx.doi.org/10.1002/cncr.28397
4. Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012; 30:199-211; PMID:22385990; http://dx.doi.org/10.1016/j.urolonc.2011.10.010
5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59:997-1008; PMID:21458150; http://dx.doi.org/10.1016/j. eururo.2011.03.017
6. De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes JA, Vegt PD, Debruyne FM, Ruitenberg EJ. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991; 33:411-6; PMID:1878894; http://dx.doi.org/10.1007/BF01741603
7. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150:1018-23; PMID:8102183
8. Riemensberger J, Böhle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002; 127:20-6; PMID:11882028; http://dx.doi.org/10.1046/j.1365-2249.2002.01734.x
9. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002; 167:364-7; PMID:11743357; http://dx.doi.org/10.1016/S0022-5347(05) 65469-9
10. de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155:477-82; PMID:8558640; http://dx.doi.org/10.1016/S0022-5347(01)66424-3
11. Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 2003; 131:206-16; PMID:12562379
12. Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003; 21:17-26; PMID:12668155; http://dx.doi.org/10.1016/S1043-4666(02)00490-8
13. rd, Eisenbraun MD, Fraser JD, O'Donnell MA, Luo Y. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette- Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. J Urol 2012; 187:2228-35; PMID:22503050; http://dx.doi.org/10.1016/j.juro.2012.01.030
14. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175:2004-10; PMID:16697786; http://dx.doi.org/10.1016/S0022-5347(06)00264-3
15. Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009; 1:281-8; PMID:20046960; http://dx.doi.org/10.2217/1750743X.1.2.281
16. Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011; 18:113-20; PMID:21091799; http://dx.doi.org/10.1111/j.1442-2042.2010.02678.x
17. Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE. Bacillus Calmette-Guérin Failure in Patients with Non-Muscle-invasive Urothelial Carcinoma of the Bladder May Be Due to the Urologist's Failure to Detect Urothelial Carcinoma of the Upper Urinary Tract and Urethra. Eur Urol 2013; (Forthcoming); PMID:24144432; http://dx.doi.org/10.1016/j.eururo.2013.09. 049
18. Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 2012; 4:37ra72; PMID:22674550; http://dx.doi.org/10.1126/ scitranslmed.3003586
19. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13:e32-42; PMID:22225723; http://dx.doi.org/10.1016/S1470-2045(11) 70155-3
20. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007; 104:3967-72; PMID:17360461; http://dx.doi.org/10.1073/pnas. 0611618104
21. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12:5442-7; PMID:17000678; http://dx.doi.org/10.1158/1078-0432.CCR-06-0527
22. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001; 7:23-31; PMID:11205913
23. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31:849-57; PMID:18833002; http://dx.doi.org/10.1097/CJI.0b013e3181891574
24. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 2012; 42:591-600; PMID:22636067; http://dx.doi.org/10.1093/jjco/hys069
25. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy 2011; 3:1223-33; PMID:21995573; http://dx.doi.org/10.2217/imt.11.100
26. Nardelli-Haefliger D, Dudda JC, Romero P. Vaccination route matters for mucosal tumors. Sci Transl Med 2013; 5:fs4; PMID:23408051; http://dx.doi.org/10. 1126/scitranslmed.3005638
27. + T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:72ra20; PMID:23408053; http://dx.doi.org/10.1126/scitranslmed.3004888
28. Decrausaz L, Domingos-Pereira S, Duc M, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer 2011; 129:762-72; PMID:21384340; http://dx.doi.org/10.1002/ ijc.25973
29. Decrausaz L, Revaz V, Bobst M, Corthésy B, Romero P, Nardelli-Haefliger D. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer 2010; 126:2469-78; PMID:19816937
30. Domingos-Pereira S, Derré L, Warpelin-Decrausaz L, Haefliger JA, Romero P, Jichlinski P, Nardelli-Haefliger D. Intravaginal and Subcutaneous Immunization Induced, Vaccine Specific CD8 T Cells and Tumor Regression in the Bladder. J Urol 2013; (Forthcoming); PMID:23954582; http://dx.doi.org/10.1016/j. juro.2013.08.009
31. Naz RK. Female genital tract immunity: distinct immunological challenges for vaccine development. J Reprod Immunol 2012; 93:1-8; PMID:22154945; http://dx.doi.org/10.1016/j.jri.2011.09.005
32. Chan CY, St John AL, Abraham SN. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 2013; 38:349-59; PMID:23415912; http://dx.doi.org/10.1016/j.immuni.2012.10.019
33. Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 2013; 6:393-404; PMID:22968420; http://dx.doi.org/10.1038/mi.2012.83
34. Decrausaz L, Pythoud C, Domingos-Pereira S, Derré L, Jichlinski P, Nardelli-Haefliger D. Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8(+) T cells. Oncoimmunology 2013; 2:e22944; PMID:23483225; http://dx.doi.org/10.4161/onci.22944
35. Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it? Nat Clin Pract Urol 2008; 5:117; PMID:18322472; http://dx.doi.org/10.1038/ncpuro1061